Wednesday, April 23, 2025

Egnyte & Espero Partner on AI-Powered Clinical Trial Solutions

Related stories

BlackCloak Unveils First ID Tool to Fight Deepfake Threats

BlackCloak has launched an industry-first Identity Verification solution to...

BigID Launches AI Privacy Console for Leaders and Risk Intel

BigID, the leading platform for data security, privacy, compliance,...

HiddenLayer Launches AISec 2.0 for Enterprise AI Security

Launch coincides with RSAC 2025 and introduces Model Genealogy, AIBOM,...

Pentera 7 Adds Scalable Testing, AI Reporting for Enterprise

Distributed Attack Orchestration supports parallel security testing in organizations with...

Healthee Raises $50M to Transform Health Benefits

Healthee, the AI-powered platform transforming the health benefits experience,...
spot_imgspot_img

Egnyte, a leader in secure content collaboration and governance, and Espero, a pioneer in clinical trial eProtocol innovation, announced a strategic partnership that combines their advanced artificial intelligence (AI) capabilities to revolutionize clinical trial protocol development and management.

This collaboration integrates Egnyte’s Content Intelligence Engine and AI Copilot technology with Espero’s AI-enabled Insights Driven Protocol Platform to deliver a comprehensive, intelligent solution throughout the clinical trial lifecycle. The integration ensures a single source of truth for all protocol-related documents and streamlines workflows with built-in regulatory features, reducing the risk of inconsistencies or errors when managing multiple systems.

“Partnering with Espero marks a significant milestone in our commitment to innovation that benefits the life sciences sector,” said Abhay Kini, director of Life Sciences at Egnyte. “By combining our powerful content collaboration platform with Espero’s groundbreaking eProtocol solutions, we will enable clinical trial organizations to achieve greater efficiency, compliance, and insights, setting a new standard for the future of clinical trial management.”

Also Read: Medrio Launches AI Reporting to Address Data Challenges

The integrated platform leverages both companies’ AI technologies to deliver powerful new capabilities, including:

  • Unified Document Management: The integration will centralize clinical protocols and study documents within Egnyte’s secure environment, enhancing collaboration and reducing data silos.
  • Automated Workflows: Document flows between Espero and Egnyte will ensure version control and a clear audit trail while minimizing manual data entry errors.
  • Compliance and Audit Readiness: Egnyte’s GxP-compliant environment will ensure adherence to regulatory standards and maintain comprehensive audit trails for enhanced audit readiness.
  • Collaborative Editing and Review: Multiple stakeholders can work on protocol documents simultaneously, benefiting from real-time co-editing and streamlined review processes.
  • Enhanced Security and Access Control: Robust security features protect sensitive clinical data with granular access controls for managing document permissions.
  • Intelligent Content Management: The integration will utilize Egnyte’s AI capabilities to organize and retrieve protocol-related content from Espero, facilitating quick access to relevant information.

“We are equipping life sciences organizations with the tools they need to streamline protocol development and enhance data integrity by integrating automation processes and our AI-driven insights with Egnyte‘s secure content governance,” said Kimberly Tableman, CEO of Espero. “This partnership is another step in our mission to push the boundaries of what’s possible in clinical innovation.”

Source: Globenewswire

Subscribe

- Never miss a story with notifications


    Latest stories

    spot_img